40 mcg igf 1 lr3 IGF-1 – Research Peptide IGF-1 LR3 in Aesthetic and

We also find no difference in White and Asian populations for events of hepatic complications

The Phase III REDEFINE 4 trial marked the first direct comparison between leading obesity treatments: 84-week, open-label, randomized study CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) vs Tirzepatide 15mg 809 adults with obesity (BMI 30), mean baseline weight 114.2 kgs Primary endpoint: relative percent change in body weight at week 84 Weight loss results under efficacy estimand (AKA only the people that stayed adherent): CagriSema: 23.0% Zepbound: 25.5% Weight loss results under treatment regimen estimand (AKA everyone in the trial, regardless of adherence): CagriSema: 20.2% Zepbound: 23.6% CagriSema failed to meet non-inferiority to Zepbound in this trial

Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M , Kolitz J, Gabrilove J, et al

Supply Chain: Dispatched with a cold pack